logo-loader

Avalon GloboCare preparing to begin its first in-human clinical trial to test coronavirus vaccine

Published: 12:01 25 Aug 2020 EDT

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr David Jin updated investors on the progress of its research and development programs in cell therapy and Covid-19-related initiatives.

Dr Jin explains how the New York-based group is getting reading to initiate its first in-human clinical c in the beginning of 2021.

Avalon Globocare Corp seeing success working in the celltech space

Avalon GloboCare CEO (NASDAQ:AVCO) Dr. David Jin sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference. The company is a clinical-stage CellTech bio-developer specializing in cellular therapeutics. Dr Jin talked about success in 2019 and what he expects in 2020.

on 10/12/19